EGFR and non-small cell lung carcinoma: In this study, Sharma and colleagues used the well established EGFR-mutant NSCLC cell line PC9 and observed that a small fraction (range 0.3–5%) of quiescent cells remained viable after nine days of treatment with the first generation EGFR-TKI erlotinib.